188 related articles for article (PubMed ID: 24854628)
1. ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
Akao H; Polisecki E; Schaefer EJ; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Packard C; Buckley BM; Kajinami K;
Atherosclerosis; 2014 Jul; 235(1):176-81. PubMed ID: 24854628
[TBL] [Abstract][Full Text] [Related]
2. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
[TBL] [Abstract][Full Text] [Related]
3. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
[TBL] [Abstract][Full Text] [Related]
4. Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease.
Li J; Wang LF; Li ZQ; Pan W
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):567-70. PubMed ID: 19673941
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
Atherosclerosis; 2012 Feb; 220(2):413-7. PubMed ID: 22189199
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Voora D; Shah SH; Reed CR; Zhai J; Crosslin DR; Messer C; Salisbury BA; Ginsburg GS
Circ Cardiovasc Genet; 2008 Dec; 1(2):100-6. PubMed ID: 20031551
[TBL] [Abstract][Full Text] [Related]
8. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
9. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
10. ATP-binding cassette transporter A1 (ABCA1) R219K (G1051A, rs2230806) polymorphism and serum high-density lipoprotein cholesterol levels in a large Japanese population: cross-sectional data from the Daiko Study.
Mokuno J; Hishida A; Morita E; Sasakabe T; Hattori Y; Suma S; Okada R; Kawai S; Naito M; Wakai K
Endocr J; 2015; 62(6):543-9. PubMed ID: 25877294
[TBL] [Abstract][Full Text] [Related]
11. Gender specific association of ABCA1 gene R219K variant in coronary disease risk through interactions with serum triglyceride elevation in Turkish adults.
Çoban N; Onat A; Kömürcü Bayrak E; Güleç Ç; Can G; Erginel Ünaltuna N
Anadolu Kardiyol Derg; 2014 Feb; 14(1):18-25. PubMed ID: 24084154
[TBL] [Abstract][Full Text] [Related]
12. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study of statin therapy and cholesterol reduction.
Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Polisecki E; Muallem H; Maeda N; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Westendorp RG; de Craen AJ; Buckley BM; Ordovas JM; Schaefer EJ;
Atherosclerosis; 2008 Sep; 200(1):109-14. PubMed ID: 18261733
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial.
Matthan NR; Resteghini N; Robertson M; Ford I; Shepherd J; Packard C; Buckley BM; Jukema JW; Lichtenstein AH; Schaefer EJ;
J Lipid Res; 2010 Jan; 51(1):202-9. PubMed ID: 19578163
[TBL] [Abstract][Full Text] [Related]
18. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.
Sacks FM; Tonkin AM; Craven T; Pfeffer MA; Shepherd J; Keech A; Furberg CD; Braunwald E
Circulation; 2002 Mar; 105(12):1424-8. PubMed ID: 11914249
[TBL] [Abstract][Full Text] [Related]
19. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
Sasaki S; Nakagawa M; Nakata T; Azuma A; Sawada S; Takeda K; Asayama J;
Circ J; 2002 Jan; 66(1):47-52. PubMed ID: 11999665
[TBL] [Abstract][Full Text] [Related]
20. A Common R219K Variant of ATP-Binding Cassette Transporter A1 Gene Alters Atherometabolic Traits in Pregnant Women With Gestational Diabetes Mellitus.
Tang F; Guan L; Liu X; Fan P; Zhou M; Wu Y; Liu R; Liu Y; Liu S; Li D; Bai H
Front Endocrinol (Lausanne); 2021; 12():782453. PubMed ID: 34975757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
